Courtney D. DiNardo, MD, on Clinical Implications of Venetoclax and Azacitidine for Treatment-Naive Patients With AML

Posted: Tuesday, July 7, 2020

Courtney D. DiNardo, MD, of The University of Texas MD Anderson Cancer Center, discusses her findings on the benefits of venetoclax plus azacitidine vs azacitidine alone, concerns about tumor-lysis syndrome, and the need to delay treatment due to toxicity.